Nebivolol in Patients With Systolic Stage 2 Hypertension

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Forest Laboratories
• Treatments: Nebivolol

Criteria

Inclusion Criteria:

• male of female, 18 to 64 years of age at screening

• mean seated heart rate at least 60 bpm

• diagnosed systolic stage 2 hypertension

• unremarkable physical exam findings

Exclusion Criteria:

• high risk due to secondary hypertension or former stage 3 hypertension by JNC6

• concurrent conditions (reno, cardiovascular, obesity, thyroid, etc)

• currently taking medication that cannot be stopped during the course of the study

• participating other clinical trials

• member of the study center personnel

• documented drug abuse

• contra indication to beta blocker

• abnormal lab finding

• poor compliance

• other conditions judged by investigator that is not suitable for the study